Kymera Therapeutics Q3'26 Results Expected October 29
Kymera Therapeutics is scheduled to report Q3'26 results on October 29. EPS is estimated at $(1.27).
Related stories
MSC Nears Deal to Acquire 80% Stake in Meyer Werft, Spiegel Reports
The German government and Lower Saxony are nearing a deal giving Geneva-based shipping group MSC the right to acquire about 80% of the German shipbuilder's shares, Spiegel reported
M impact | EQUITY | Nov 14, 2026, 12:11 PM UTC
Advanta Agrees to Acquire Hytech Egypt Holding Company
Advanta entered into an agreement on Aug. 15, 2026, to acquire Hytech Egypt USA LLC, the holding company of Misr Hytech Seed International, from Helios Investment Partners and The
M impact | EQUITY | Nov 14, 2026, 11:51 AM UTC
Microsoft Restores Microsoft 365 After Global Outage
Microsoft said it restored Microsoft 365 services after a global outage disrupted Outlook, Teams and other applications for more than 24 hours. The company said the disruption was
M impact | EQUITY | Nov 14, 2026, 10:41 AM UTC
Microsoft Restores Service After Widespread Outage
Microsoft said full service to its products was restored as of early Saturday, including processing undelivered emails.
M impact | EQUITY | Nov 14, 2026, 09:57 AM UTC
Microsoft Restores Services After Hourslong Global Outage
Microsoft said services were fully restored after an hourslong global outage.
M impact | EQUITY | Nov 14, 2026, 09:12 AM UTC
Rs.4K cr Ramayana movie VFX maker parent Prime Focus shares in focus after 14x profit jump in Q2; stock up 61% in a year
New Delhi, Nov. 14 -- Prime Focus Ltd, the parent company of visual effects and animation studio DNEG, is likely to remain in focus on Monday after announcing its September-quarter
L impact | EQUITY | Nov 14, 2026, 09:04 AM UTC